Given Sobi's cash flow generation from its hemophilia business and mature product Synagis, the firm ended 2024 with a net debt/EBITDA ratio of 1.6 times. We expect the firm can support this level of ...
AstraZeneca reports mixed results in the fourth quarter. It gains in pre-market after assuring investors that the business ...
Strong momentum in FY 2024 with Total Revenue and Core EPS up 21% and 19% respectively AstraZeneca: Revenue and EPS summary FY 2024 % Change Q4 2024 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback